Charter Medical, Ipratech, and APIcells to Collaborate on a Fully Automated Perfusion Platform

Charter Medical, Ipratech, and APIcells to Collaborate on a Fully Automated
Perfusion Platform

MANCHESTER, Conn., Sept. 16, 2013 (GLOBE NEWSWIRE) -- Charter Medical, Ltd., a
division of Lydall, Inc. (NYSE:LDL), announced today that it will be
collaborating with Ipratech SA and APIcells, Inc. by combining their
respective expertise in single-use technology, upstream process engineering,
and instrumentation control. Through this collaboration, the companies will
provide customers with turnkey, fully automated, scale-free perfusion platform
solutions for disposable and classical bioreactors.

As part of this collaboration, Charter Medical will be the exclusive global
distributor of the portfolio that includes CYTOSYS and CYTOPERF technologies.
CYTOSYS is a fully remote control system designed for real-time control and
monitoring of batch, fed-batch, and continuous cell culture processes. The
CYTOPERF technology is the first commercial, fully disposable cell retention
device to address high-density perfusion processes.

Additionally, Charter Medical, Ipratech, and APIcells will be collaborating on
the development of a continuous cell cultivation platform. The aim of the
relationship is to provide customers with innovative solutions for continuous
manufacturing in response to strong market demand. Dale Barnhart, President
and CEO of Lydall, said, "We are very excited about this opportunity as it
complements our existing portfolio and allows us to continue to better serve
our customers." Mr. Barnhart further noted that, "This collaboration
demonstrates Charter Medical's commitment to be a complete solution provider
to the bio-processing industry."

Olivier Berteau, CEO of APIcells; and David Sergeant, CEO of Ipratech
commented, "Collaborating with Charter Medical best complements our
technological vision and, from a strategic perspective, allows us to most
optimally address market demand."

Lydall, Inc. is a New York Stock Exchange listed company, headquartered in
Manchester, Connecticut. The Company, with operations in the U.S., France, and
Germany and offices in Europe and Asia, focuses on specialty engineered
products for the thermal/acoustical and filtration/separation markets. Charter
Medical, Ltd., a Lydall subsidiary, is a vital fluids management company
focused on providing products to separate, contain and transport vital fluids
in the blood and cell therapy market and the biotech and pharmaceutical
industries. Lydall® is a registered trademark of Lydall, Inc. in the U.S. and
other countries. All product names are trademarks of Lydall, Inc. or Charter
Medical, Ltd.

CONTACT: David D. Glenn
         Director of Business Development and
         Investor Relations
         Telephone 860-646-1233
         Facsimile 860-646-4917
         info@lydall.com
         www.lydall.com

company logo